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Abstract Exacerbations arethekeydriversinthe costs ofchronicobstructivepulmonarydisease (COPD).The objec-
tivewas to examine the costs of COPD exacerbations in relation to differing degrees of severityof exacerbations and of
COPD.Weidentified 202 subjectswithCOPD, definedaccording tothe BTSand ERScriteria.Exacerbationsweredivided
intomild (self-managed), mild/moderate (telephone contact with a health-care centre and/or the use of antibiotics/sys-
temic corticosteroids), moderate (health-care centre visits) and severe (emergency care visit or hospital admission). Ex-
acerbations were identified by sending the subjects a letter inquiring whether they had any additional respiratory
problems or influenza the previouswinter.At leastone exacerbationwas reported by 61subjects, whowere then inter-
viewedaboutresourceuse for these events.The averagehealth-care costsperexacerbationwere SEK120 (95%CI=39^
246), SEK 354 (252^475), SEK 2111 (1673^2612) and SEK 21852 (14436^29825) formild, mild/moderate, moderate and se-
vere exacerbations, respectively. Subjects with impaired lung function experiencedmore severe exacerbations, which
was alsore£ectedinthe costofexacerbationsper severityofthe disease during the 412month studyperiod (ranging from
SEK224 formildto SEK13708 for severe cases,median SEK 940).Exacerbations accountfor 35^45% ofthetotalpercapita
health-care costs for COPD.In conclusion, costs varied considerablywiththe severityofthe exacerbation aswell aswith
the severity of COPD.The prevention of moderate-to-severe exacerbations could be very cost-e¡ective and improve
the qualityof life.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1334, available online athttp://www.idealibrary.comon
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Chronic obstructive pulmonary disease (COPD) is a
common disease among adults and the elderly. In devel-
oped countries the estimatedprevalence is 4^6% among
adultmales and1^3% among adult females, and this pre-
valence, particularly among women, is increasing (1^3).
The dominant risk factor is smoking, a widely accepted
¢gure being the development of COPD by 15% of smo-
kers. However, according to the recent U.S. National
Health and Nutrition Study (NHANES) III and the Ob-
structive Lung Diseases in Northern Sweden Studies
(OLIN), sooner or later as many as 50% of smokers may
develop COPD (4,5). COPD is also a disease which isCorrespondence should be addressed to: Fredrik Andersson, PhD,
Health Economics &Outcomes Research, AstraZeneca R&D, Lund,
SE-22187 Lund, Sweden.Fax: +46 46 337553;
E-mail: fredrik.l.andersson@astrazeneca.comdemanding in terms of health-care resources
consumed (6,7), the key cost driver being acute exacer-
bations (7,8).
COPD is a slowly progressive disease. Acute exacer-
bations, or acute worsening of respiratory symptoms,
occur commonly in subjects with COPD (8). These ex-
acerbations di¡er in severity. It has been estimated that
the average COPD patient experiences about one to
four acute exacerbations per year (9). Health-care utili-
sation is usually signi¢cantly increased during an exacer-
bation (7,8,10,11) and the quality of life of the individual is
considerably reduced (12). Furthermore, exacerbations
are the most frequent cause of hospital admission and
death among subjects with COPD (13).
A reduction in the number of exacerbations of COPD
has been identi¢ed as an important outcome in national
and international guidelines and in the clinical literature
(8,14^18). Unfortunately, exacerbations are described
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tions are of limited consistency. Hence, at present there
is no universally accepted clinical de¢nition of what con-
stitutes an acute exacerbation of COPD or of how to
grade the severityof such anexacerbation.There are lim-
ited data about the incidence of exacerbations of di¡er-
ing severity. Moreover, data on the economic
consequences of exacerbations are very scarce.
The purpose of this paper is to examine the costs of
COPD exacerbations in relation to di¡ering degrees of
severity of exacerbations and of COPD.
MATERIALANDMETHODS
Sample
Details of the study samplewere described in a previous
publication (6). Brie£y, the sample was generated from
large-scale studies, which started in 1985, of the epide-
miologyof obstructive pulmonary diseases and type1 al-
lergy in northern Sweden (the OLIN studies). Today,
longitudinal studies of a number of cohorts are under
way, including a total of approximately 40 000 children,
adults and elderly individuals (19^23).
The inclusion criterion, a diagnosis of COPD, was
based on spirometry testing.This diagnosiswasprimarily
de¢ned according to the BritishThoracic Society’s (BTS)
criteria: an FEV1/VC ratio o70% and an FEV1 o80% of
predicted values.BTS divides COPD intomild,moderate
and severe disease (16). In addition, personswith an FEV1/
VCratioo70% and anFEV1X80%of thepredictedvalue
were also included in the study.The inclusion of thismild
type of COPD is in full agreementwith the recentGlobal
Initiative of Chronic Obstructive Pulmonary Disease
(GOLD) guidelines (14) and corresponds approximately
to the criteria of the European Respiratory SocietyTABLE 1. Study sample by severityof COPD.Numberof subject
o 40%
Subjects diagnosedwith COPD-OLIN 41
Contacted subjects for the COI study (6)a 37
Enrolled subjects for the COI study (6)b 28
Completing subjects in the COI study (6) 24
Study sample
Subjects receivingquestionnaire 24
Non-responders, dead 0
Non-responders, other reasonb 0
Participated in the exacerbation study 24
aAlive.
bTheindividualswho didnotparticipateweretoo ill, werenotlivin
not speak Swedish or refused to participate in the COI study.(ERS) for mild COPD (17). Subjects with other diseases
which explained their impaired pulmonary function
were excluded. Those with chronic pulmonary
obstruction who referred to themselves as asthmatics
were included, which is supported by the BTS guidelines
(16).
The number of patients diagnosed with COPD in the
OLIN studies is about 800, although when stratifying by
age (range 28^80 years) anddisease severity (FEV1%pre-
dicted 18^118), some strata contain relatively few sub-
jects. Accordingly, all subjects with an FEV1 o60% of
predicted values were included in the study cohort. In
the case of subjectswith an FEV1X60% of the predicted
value, a random samplewas drawn fromeach stratum to
give a study cohort of a su⁄cient size to allow themea-
surement of signi¢cant di¡erences between di¡erent
groups of severity. By subsequently assigning weights to
our strata based onprevalence, we avoidedbias originat-
ing from our selection, since the weighted strata gener-
ated theweighted results according to the prevalence of
subjects of a similar age and degree of severity.The study
population is shown inTable 1. As can be seen from the
table, the random sample was ¢rst used in a recently
completed cost-of-illness study (6).This very same sam-
plewas subsequentlyused for thepresentcostof exacer-
bation study.
The study was approved by the ethics committee at
the Ume6 University and the University Hospital of
Northern Sweden in Ume6.
Study design
The 202 subjectswithCOPDwere sent a letter inMarch
2000, which asked themwhether they had needed to do
any of the following because of additional respiratoryswith andwithoutexacerbation
FEV1% predicted
40^59% 60^79% X80% All
105 294 339 779
99 108 49 293
72 79 34 213
68 76 34 202
68 76 34 202
1 1 0 2
4 3 2 9
63 72 32 191
gatthegiven address, couldnotbereachedby telephone, did
TABLE 2. Unitcosts (SEK,1999)
Resource Costs
Medicine (28) According to
speci¢eduse
Visit/contact, physician, per visitor
contact
1170
Visit/contact, other personnel, per visit
or contact
340
Hospitalisation
Respiratory 2810
General 3650
Intensive care unit 5440
Primarycare centre 3030
Transportation, per10 km 15
Ambulance transport, per transport 2479
Sources:Countycouncil,Norrbotten,Sweden and (6).
702 RESPIRATORYMEDICINEproblems or in£uenza during the previous winter (No-
vember^March):
K takemoremedication for respiratory disease,
K take time o¡ work,
K make an unplanned visit to a nurse or doctor (at a
GP’s surgery or hospital),
K visit an emergency care unit, or
K stay overnight in a hospital.
Twoweeks later a reminderwas sentout.The subjects
who answered ‘yes’ to any of these questions were in-
cluded in the study.
Methods
A structured telephone interview, using a specially de-
signed and pilot-tested questionnaire, was conducted by
a registered nurse (A-C J). The questionnaire focused
strictlyon extra resourcesuse in connectionwith the re-
spiratory problems.The incremental costs due to an ex-
acerbation were included, while the costs of day-to-day
COPD treatment were excluded.Visits and hospitalisa-
tions were veri¢ed by the patient records since these
two itemshavebeen found to account for a large propor-
tion of the total health-care costs for COPD, irrespec-
tive of the country involved (24^27).
The following de¢nitions of exacerbationwere used:
K Mild exacerbationswere de¢ned as those self-managed
by the subject by increasing the dose of the current
medication (including adding OTCmedication).
K Mild/moderate exacerbations were those requiring
telephone contact with a health-care centre and/or
treatment with antibiotics or systemic
corticosteroids.
K Moderate exacerbations required a visit to a GP or to
an outpatient clinic.
K Severe exacerbations required visits to an A&E
department or hospital admission.
An exacerbation was classi¢ed according to the high-
est level of resource use, e.g. a telephone call followedby
a visit to a GPwas classi¢ed asmoderate.The de¢nitions
resemble the de¢nitions proposed by a working group
convened following the 1999 Aspen Lung Conference
(8), with the exception of the two milder types, which
were combined into one type of exacerbation.
We used the BTS and ERS staging systems to divide
the severity of COPD into: o40, 40^59, 60^79 and
X80% FEV1predicted.
Analysis
The resources recorded were medicine, health-care
contacts, visits to A&E departments, hospitalisation
and transportation to the health-care provider. Re-source use was multiplied by the1999 unit prices shown
inTable 2, which re£ect local prices in northern Sweden.
The exchange rates on January 3, 2002 were USD 1 =
SEK10.23 and one euro = SEK 9.25.
Homogeneity of categorical datawas tested using chi-
square tests (e.g. di¡erences in occupation, smoking ha-
bits, risk of experiencing exacerbations, etc). Compari-
sons of cost data between several groups were made
using analyses of covariance (ANOVA model). Simulta-
neous comparisons of group means were made using
multiple comparison analysis (MCA) (29). A P-value less
than 0.05 was considered to be statistically signi¢cant.
In calculating prevalence-weighted average costs as
well as societal costs, we used previously estimated na-
tional prevalence estimates, broken down by disease se-
verity and o⁄cial population data (6,30,31). The
estimated Swedish total COPD prevalence was about
678 000 individuals (6). These detailed prevalence num-
bers were used to weight our sample, as we sampled all
patients below FEV160%. In this way, we arrived at aver-
age values that should re£ect the distribution of COPD
patients in Sweden (4,6,31).
RESULTS
Patient description
The ¢nal response rate was 95% (Table1).Of the11non-
participants, two had died since the previous contact.
The remaining nine subjects did notrespond or wereun-
willing to participate even after a secondreminder. A to-
tal of 61subjects (32%) reported that they had needed to
do one ormore of the activities listedunder studydesign
(Fig.1).
Five additional subjects reported having experienced
additional respiratory problems and/or in£uenza,
FIG. 1. Exacerbationrate by severityof COPD.
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were excluded from the analysis, however, because
it was later established that they either did not consume
any additional resources (hence by our de¢nition did
not experience an exacerbation, three subjects
reporting in total four exacerbations) or were
mentally confused and therefore unable to provide any
reliable information (two subjects reporting four exacer-
bations).
Exacerbations in relation to demography
The analyses are based on 61 subjects (out of the191 re-
sponders), who accounted for a total of 75 exacerba-
tions. There were no signi¢cant di¡erences in age,
gender and smoking habits among those who experi-
enced an exacerbation and those who did not. Subjects
who experiencedone ormore exacerbationshad a signif-TABLE 3. Study sample demographyin subjectswith andwitho
Subjectsw
exacerba
Numberof subjects 130
Mean age inyears (STD) 63.3 (
Min ^ max 28^80
Mean FEV1% of predicted (STD) 64.1 (
Min ^ max 25^118
Gender (%male/female) 62/38
Smokinghabits
Non-smokers (%) 18
Ex-smokers (%) 43
Smoker (%) 38
Occupation
Employed, full-time (%) 28
Employed, part-time (%) 1
Other (retired, unemployed, etc.) (%) 71icantly lower FEV1as a percentage of thatpredicted than
those who did not experience any exacerbations
(P=0.028, Table 3). In addition, they were to a lesser ex-
tentpart of the labourmarket. About 5% of the subjects
without exacerbations were registered as disabled due
to their disease, compared with 21% of the 61 subjects
with exacerbations (Po0.001).
Half of those with severe COPD reported having had
one or more exacerbations, compared with only 25% of
those with very mild or mild COPD (Fig.1).On average,
32% of the subjects reported an exacerbation during this
period.
The risk of experiencing exacerbations di¡ered signi¢-
cantly between the FEV1 classes when adjusting for ex-
acerbation types (P=0.002). For example, subjects with
severe COPDreported on average one severe exacerba-
tion during the study period, comparedwith 0^0.125 for
the verymild-to-moderate subjects (Table 4).utexacerbations
ithno
tions
Subjectswith one
ormore
exacerbation
Di¡erence
61
12.9) 64.6 (10.8) ns
43^80
18.8) 56.9 (20.8) P=0.028
18^100
51/49 ns
ns
13
56
31
13
3
84 P=0.004
TABLE 4. Number and severityof exacerbationsby severityof COPD
FEV1
Exacerbations o 40%
(n=12)
40^59%
(n=24)
60^79%
(n=18)
X 80%
(n=7)
All
(n=61)
Mild
(self-managed)
2 7 8 6 23
Mild/moderate
(telephone contact and/or antibiotic
and/ororal steroid)
4 5 1 0 10
Moderate
(health-care outpatient visit)
5 10 8 2 25
Severe
(emergency visitorhospitalisation)
12 3 2 0 17
All 23 25 19 8 75
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As expected, resource use for the four di¡erent types of
exacerbations di¡ered.The average number ofmedicines
used during a mild exacerbation was 1.6, slightly lower
than during mild/moderate (2.7) and moderate (2.6) ex-
acerbations, but much lower than for severe exacerba-
tions (4.2). Some medications were added compared to
regular treatment (e.g. antibiotics), whereas for some
the dose was increased (e.g. short-acting b2-agonists).
The main groups of medicines were short- and long-act-
ing b2-agonists (80% of exacerbations, mainly salbuta-
mol), antibiotics (36%, mainly doxycycline), closely
followed by systemic corticosteroids (34%, predniso-
lone). Inhaled corticosteroids, anticholinergics and
xanthines were used in 23, 21 and 17% of the exacerba-
tions, respectively. OTC medication (e.g. painkillers,TABLE 5. Mean (median) costs perexacerbation according to se
Mild
(n=23)
Mild/Moderate
(n=10)
Costofmedicine 120 (36) 252 (265)
Costof visits/contacts N/A 102 (110)
Transportation N/A N/A
Hospitalisation cost N/A N/A
Directcosts
Mean 120 354
95% CI 39^246 252^475
Median 36 375
STD 264 194
Note:Combining the twomilder types of exacerbations result
average takesinto accountthe proportion of each severitygrade
tionnot applicable.cough & cold remedies) was also used to a large extent
(48% of exacerbations).
The number of phone contacts ranged from 0.29 for
severe exacerbations to1.2 for mild/moderate exacerba-
tions. The number of health-care visits was 0.65 for se-
vere exacerbations and 1.56 for moderate
exacerbations.Thus, we ¢nd a certain interchangeability
between di¡erent forms of resource use. The average
length of stay in hospital for a severe exacerbation was
6.6 days (median 6 days).
The costs of treating COPD exacerbations increased
considerably with severity (Table 5). Severe exacerba-
tions were on average about 10 times more expensive
than moderate and 60 times more expensive than mild/
moderate exacerbations. Weighted average exacerba-
tion costs show that hospitalisation accounts for two-
thirds of the total costs (Fig. 2).verity (SEK,1999)
Exacerbationtype
Moderate
(n=25)
Severe
(n=17)
Weighted average,
per exacerbation (%)
291 (203) 400 (271) 181 (6%)
1778 (1170) 576 (0) 769 (24%)
41 (9) 523 (158) 80 (3%)
N/A 20352 (21900) 2106 (67%)
2111 21852 3163 (100%)
1673^2612 14 436^29825 2649^3657
1483 22869 ^
1235 16 645 ^
s in an average cost of SEK191 (median SEK 69).Theweighted
inthe general Swedish COPD population.N/A: due to de¢ni-
FIG. 2. Percentof total costs of exacerbations.
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During the 4 12 month study period, the total per capita
costs due to exacerbations, i.e. including all types of ex-
acerbations and weighting them according to frequency,
varied from SEK13708 in subjects with severe COPD to
SEK 294 in those with very mild COPD (Table 6). The
subjects with the lowest FEV1% predictedwere a source
of signi¢cantly higher costs than those in the three other
groups of disease severity, mainly because they experi-
enced a higher rate of severe exacerbations. The preva-
lence-weighted 412 month cost of all (weighted)
exacerbations for the average COPD subject was SEK
940 (95%CI=428^1555).Thismeans that during this par-
ticular winter the average COPD subject in this sample
(and also in Sweden since we weighted the cost by na-
tional prevalence estimates) consumed extra resources
amounting to SEK 940, all due to exacerbations.
At a national level, using recent prevalence estimates
for each severity category (4,6,31) plus o⁄cial population
data (30) and assuming no seasonal variation, the esti-
mated annual cost of exacerbations for all individuals
with COPD in Sweden was about SEK 1.7 billion (95%
CI; SEK 0.77^2.8).TABLE 6. Mean (median) costs per 412months according to seve
C
o40% 40^59%
Costofmedicine 514 60
Costof visits/contacts 422 367
Transportation 263 13
Hospitalisation cost 12 510 263
Directcosts:Mean 13708 702
95% CI 3580^27509 334^1203DISCUSSION
This studyexamined the costs of COPD exacerbations in
clinical practice fromvarious aspects.Firstly, therewas a
di¡erence between the population reporting an exacer-
bation and those who did not. Subjects reporting a re-
cent exacerbation had lower lung capacity andwere to a
lesser extent part of the labour market. Secondly, sub-
jects with a lower level of lung function experienced
more, though alsomore severe, exacerbations. As a con-
sequence, this also resultedinhigher costs due to exacer-
bations in general. Thirdly, there were large cost
di¡erences between di¡ering degrees of severity, with
severe exacerbations having health-care costs more
than 10 times higher than for moderate exacerbations
and about 60 times higher than for mild/moderate ex-
acerbations. Finally, the total cost due to exacerbations
during the 412 month study period varied substantially
between di¡erent levels of disease severity F for in-
stance, severe COPD subjects experienced costs that
were more than 45 times higher than those for mild
COPD subjects.
The fact that subjects with impaired lung function re-
ported more, but also more severe, exacerbations is
in line with Rodriguez-Roisin (8), who claimed that therity (SEK,1999).
OPDSeverity Degree (FEV1)
60^79% X 80% Weighted average,
per 4.5 months (%)
30 35 54 (6%)
222 189 230 (24%)
39 1 24 (3%)
406 0 631 (67%)
697 224 940
189^1469 6^584 428^1555
706 RESPIRATORYMEDICINEclassi¢cation and costs of an exacerbation are largely re-
lated to the underlying severity of the subject’s condi-
tion.Furthermore,Miravitlles et al. (32) found FEV1to be
an important explanatory variable in both their hospital
admission and their exacerbation explanatorymodels.
Only limited previous data are available for the costs
of exacerbations in COPD. An abstractwas presented at
the1999 ERSmeeting, with data from a randomised clin-
ical study (33). Using de¢nitions that are similar to the
present study, its direct cost estimates of d15 for a mild
exacerbation (self-managed), d95 for a moderate exacer-
bation (treated by a family physician or outpatient clinic)
and d1659 for a severe exacerbation (requiring hospitali-
sation) are similar to our results. Segu¤ etal. (34) studied a
sample of 2414 Spanish patients with chronic bronchitis
who sought medical attention from their primary care
physician. The mean cost of antibiotic treatment was
$30. About 21% of patients (n=507) required a newmed-
ical visit, de¢ned as treatment failure.Of these, 154 pa-
tients were seen in A&E departments and 78 were
admitted to hospital. The mean cost associated with
these treatment failureswas $404. Pechevis et al. (35) es-
timated the costs associated with recurrent respiratory
infections in 244 French subjects with chronic obstruc-
tive bronchitis. The direct health-care costs per acute
exacerbation were estimated to be FRF 3289 (about
SEK 4600), of which 60% were hospital-related.Tiri and
Grossi (36) put the costs of diagnostics andmedical ser-
vices and of medication (i.e. excluding hospitalisation) at
about ITL 638 000 (about SEK 3000) in 54 Italian COPD
subjects with exacerbations. About 50% of the overall
¢gurewas due to anti-infective treatment.
From amore global perspective,McGuire etal. (10) es-
timated for England andWales the annual excess costs of
acute exacerbations in patients with chronic bronchitis
to be d45million in1994^1995.This ¢gure represents be-
tween 0.1 and 0.2% of the National Health Service bud-
get. Similarly, Niederman et al. (37) estimated the US
costs of acute exacerbations in patients with chronic
bronchitis to be $1.2 billion for patients above the age of
65 and $419 million for patients below this age. It is di⁄-
cult to relate these exacerbation costs to the overall bur-
den of COPD in these countries as the cost-of-illness
studies employ a di¡erentmethodology than the exacer-
bation studies.
The key cost driver in our study was hospitalisation,
which accounted for 67% of the weighted costs of SEK
3136 per exacerbation.The weighted cost per exacerba-
tion could be translated into a national estimate of SEK
1.7 billion per year. To put these numbers into perspec-
tive, a previous study on the same sample and with simi-
lar methodology has estimated that the annual Swedish
health-care costs of COPD are about SEK 3.8 billion (6).
In addition to the cost of exacerbations, this amount in-
cludes the cost of regularmedicationuse, scheduledphy-
sicianvisits, etc.The annualvalue of SEK1.7 billion should,however, be interpretedwith caution in thatwehavenot
taken into account the likelihoodof seasonal variations in
the frequencyof exacerbations.For instance,Niederman
et al. (37) found that for exacerbations in chronic bron-
chitis, the rates of hospital discharges were highest
(about one-third of the total) in the ¢rst quarter of the
year. If, for example, wemake the conservative assump-
tion that because of a higher prevalence the costs of ex-
acerbations are 50% higher during our study period
(winter), compared to the other 712 months of the year,
the annual Swedish costs of exacerbations fall to SEK
1.3 billion.
The a priori de¢nitions of di¡erent types of exacerba-
tions are clear, based on the intensityof resourceuse and
noton clinical criteria. An exacerbationwas classi¢ed ac-
cording to the highest level of resource use, and this is
bound to a¡ect the level of costs. However, at present
no generally accepted de¢nition of exacerbations exists,
nor can the individual be fully trusted in this regard.With
this limitation inmind, it is comforting to note the similar
distribution of di¡erent types of exacerbations in the
clinical study by Paggiaro et al. (38).
The duration of an acute exacerbation is di⁄cult to
measure, given the day-to-day variation in symptoms. In
a study on the e¡ects of exacerbations on quality of life,
Seemungal et al. (12) found that 50% of exacerbations
werenotreportedby subjects.Recoveryof lung function
to baseline occurred after about 11 days. Our study at-
tempted to ¢nd out from the subjects the duration of
the reported exacerbation; however, it was found that
the duration reported was closely related to the dura-
tion of a givenprescription, e.g. a 7-daycourse of antibio-
tics or a 10-day course of systemic corticosteroids.
Subjects, who were often elderly, were generally not
able to recall or establish the starting and stopping dates,
as they constantly experienced symptoms of varying se-
verity.We did not measure day-to-day lung function as
did Seemungal et al.
The potential for recall bias (39) could a¡ect the re-
sults in two ways. Firstly, subjects were sent a letter in
March 2000 in which they were asked about the inci-
dence of respiratory problems during the winter season
(November^March in the north of Sweden). The sub-
jects, most of whomwere elderly, could have forgotten
early incidents of respiratoryproblems.However, we did
exclude eightexacerbationsreportedby ¢ve subjectsbe-
cause reliable data were missing, resulting in a slight un-
derestimate of the frequency. Secondly, if the actual
incident was recalled, some resource use in connection
with the exacerbation/incident could have been omitted,
such as telephone calls.The latter is likely to be a minor
problem for themoderate and severe exacerbations be-
cause all major resource use was veri¢ed by the patient
records (visits and hospital admissions, which accounted
formore than 85% of total costs).The subjectswere also
asked to bring theirmedication to thephone at the start
THECOSTSOFCOPDEXACERBATIONS 707of the interview, which increased thevalidity ofmedicine
use.
We also chose to include very mild COPD patients.
There is a risk thatwemay also have included some asth-
matic patients in our sample, especially since Table 3
shows that between13 and18% are non-smokers. How-
ever, in this particular area of Sweden a high proportion
of the inhabitantsmaybe at a serious riskof occupational
exposures as many work in the steel industry and in
mining, which are also well-known risk factors of lung
disease. About10% of our sample work or have worked
in these two sectors.Furthermore,Miratvitllesetal. (40)
reported that, in fact, 22% of a Spanish primary care
COPD samplewere non-smokers.
This study presents the ¢rst comprehensive informa-
tion on the resource use and costs of COPD exacerba-
tions, based on clinical practice.The limited earlier data
on exacerbations are to a large extent based on samples
from randomised clinical trials, samples that were se-
lectedon thebasis of a number of inclusion and exclusion
criteria.We used very few such criteria.Our data should
be particularly valid in that they re£ect a real-life setting
and the subjects were guided by an experienced nurse
during the telephone interview.The most expensive re-
source use, visits and hospital admissions, which ac-
counted for about 85% of total costs, were veri¢ed by a
review of patient journals. As for pulmonary rehabilita-
tion, this is still uncommon in Sweden, and from the per-
spective of COPD in the general population, the costs
for COPD rehabilitation are limited.That is also true for
costs of surgery for emphysema, which indeed are high
for the small number of cases that exist, but very limited
from the perspective of the general population.We did
not ¢nd any evidence of either in our sample. A second
unique aspect of this study is that we have attempted to
address the costs of mild, moderate and severe COPD
exacerbations and have compared the costs. Most pre-
vious studies in which costs have been reported have in-
volved only exacerbations admitted to hospital rather
than outpatients as in this study. A third strength is the
high response rate of 95%.
These cost estimates are only relevant for Sweden in
that they re£ect local treatment patterns, the organisa-
tion of health-care andwelfare, andrelativeprices. How-
ever, we have seen that both the absolute and relative
levels are in line with the limited existing data.The pre-
sent sample and the geographical area (Norrbotten)
studied are probably representative of the rest of
Sweden in thewayCOPD is currently treated (6). Future
prospective studies should verify and expand on our
results. Further, our follow-up period covered 412
months, i.e. the winter period. During the winter, ex-
acerbations occur more frequently, which is why our
study focused on that period.Measuring annual costs of
exacerbations requires a 12-month prospective follow-
up period.The size of the samplemay in future studies need tobe
larger than our 61 individuals with 75 exacerbations. Al-
ternatively, individuals may need to be followed for con-
siderable periods of time to accumulate enough
exacerbations to analyse.The numbers of exacerbations
studied, once division ismade in the severityof exacerba-
tions or COPD, become even smaller. At the time of the
study was planned (the autumn of 1999), however, we
had very limited a priori information regarding the fre-
quency of exacerbations, especially those of di¡erent
grades of severity. Anthonisen et al. (18) had pointed out
that COPD exacerbations occur at a rate of approxi-
mately one per year. In contrast, Seemungal et al. (12)
had reported a total annual rate of exacerbations of 2.7
per patient in a sample of moderate-to-severe patients.
An annual average of 2 exacerbations was later reported
by Miravitlles et al. (40) in a survey of Spanish health cen-
tres. Our data show a much lower value, which in part
may be due to di¡erences in de¢nitions and samples.
The fact that only one-third of the individuals experi-
enced an exacerbation is in linewith the 6-monthresults
of Paggiaro et al. (38).We did, however, try to include all
available individuals with moderate and severe COPD in
order to generate asmany exacerbations as possible.We
also give the 95% con¢dence intervals to enable the read-
er to assess the reliability of our results.
Exacerbations are the key drivers in the costs of
COPD (8). These costs are likely to increase, given the
increasing elderlypopulation (25). Also, frequent exacer-
bations have been demonstrated to a¡ect the quality of
life (12). Furthermore, Seemungal et al. (41) recently pre-
sented data which indicate that exacerbations for some
patients may also increase the general decline in lung
function. Preventing or reducing the severity of exacer-
bations is potentially very cost-e¡ective andwill also en-
hance the quality of life of subjects.There are a number
of promising drugs under development with the
potential to improve the well-being of individuals with
COPD.
In conclusion, exacerbations are costly, the costs vary-
ing considerably with the severity of the exacerbation.
Furthermore, because of a higher frequency ofmore se-
vere exacerbations, subjects with a more severe disease
have signi¢cantly higher costs for exacerbations. The
prevention of exacerbations, in particular those that
aremoderate/severe, is potentially cost-e¡ective.
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